Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
9.69 -0.78 -7.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Recent news

  • Rating change
    Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12
    \u5e02\u573a\u8d44\u8baf · 2026/8/6
  • Rating change
    Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9
    \u5e02\u573a\u8d44\u8baf · 2026/8/6
  • Rating change
    J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17
    \u5e02\u573a\u8d44\u8baf · 2026/9/29
  • Rating change
    JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25
    \u5e02\u573a\u8d44\u8baf · 2026/8/11
  • A Quick Look at Today's Ratings for AbCellera Biologics(ABCL.US), With a Forecast Between $14 to $25
    \u5e02\u573a\u8d44\u8baf · 2026/11/11
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30
    \u5e02\u573a\u8d44\u8baf · 2026/9/2
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/10
  • Rating change
    Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12
    \u5e02\u573a\u8d44\u8baf · 2026/8/7
  • Rating change
    Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12
    \u5e02\u573a\u8d44\u8baf · 2026/7/31
  • Jefferies Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $21
    \u5e02\u573a\u8d44\u8baf · 2026/10/30
  • Rating change
    JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13
    \u5e02\u573a\u8d44\u8baf · 2026/7/30
  • Rating change
    Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $11
    \u5e02\u573a\u8d44\u8baf · 2026/7/17
  • Rating change
    Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13
    \u5e02\u573a\u8d44\u8baf · 2026/9/24
  • Rating change
    JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25
    \u5e02\u573a\u8d44\u8baf · 2026/9/28
  • Rating change
    TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/8/6
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • UBS Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $18
    \u5e02\u573a\u8d44\u8baf · 2026/11/13
  • Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $14
    \u5e02\u573a\u8d44\u8baf · 2026/11/10
  • BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15
    \u5e02\u573a\u8d44\u8baf · 2026/11/10
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30
    \u5e02\u573a\u8d44\u8baf · 2026/8/12
  • Rating change
    Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $12
    \u5e02\u573a\u8d44\u8baf · 2026/5/22
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7
    \u5e02\u573a\u8d44\u8baf · 2026/6/18
  • Rating change
    BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15
    \u5e02\u573a\u8d44\u8baf · 2026/8/18
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
    TipRanks · 2026/7/16
  • Rating change
    Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $8
    \u5e02\u573a\u8d44\u8baf · 2026/5/12

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.

AbCellera Biologics discussion 0 comments

Add a comment